 |
|
|
|
|
|
|
|
 |
Results for 'Angiogenesis Modulators' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Angiogenesis Modulators
|
January 2008 |
£1390 |
100 % |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
47 % |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
May 2007 |
£2105 |
45 % |
Cardiovascular Molecular Imaging
|
July 2007 |
£130 |
35 % |
Cancer-Associated Thrombosis
|
August 2007 |
£115 |
31.5 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
25.2 % |
Apoptosis
|
January 2008 |
£1440 |
24.15 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1325 |
23.45 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
22.4 % |
Multi-Detector Computed Tomography in Oncology: Perfusion CT
|
August 2007 |
£125 |
22.4 % |
Textbook of Interventional Cardiovascular Pharmacology
|
April 2007 |
£140 |
22.05 % |
Pipeline Insight: Innovative Therapies
Targeted therapy, a clinical and commercial revolution?
|
August 2004 |
£6000 |
21.7 % |
Pipeline Insight: Colorectal Cancer
Avastin and Erbitux Pave The Way For Pipeline Targeted Therapies
|
July 2004 |
£6000 |
20.3 % |
Emerging Cancer Therapies
Markets and Business Opportunities
|
June 2002 |
£875 |
17.5 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£3510 |
16.45 % |
Pipeline/Commercial Insight: Innovative Targeted Therapies
Smart Drugs' on Target for Increasing Growth
|
October 2005 |
£8695 |
16.1 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2340 |
16.1 % |
Cancer Drug Discoveries: Prostate Cancer
|
August 2005 |
£795 |
15.75 % |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1325 |
15.05 % |
Prognostic and Predictive Factors in Gynecologic Cancers
|
September 2007 |
£55 |
15.05 % |
Current and Future Therapies for Colorectal Cancer
|
September 2005 |
£970 |
14.5 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£1665 |
14.35 % |
Melanoma Therapeutics: Which Strategy Will Take Us There?
Which Strategy Will Take Us There?
|
July 2005 |
£1665 |
13.65 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2340 |
13.3 % |
Vascular Targeting Agents: Emerging Competitors
|
February 2005 |
£1325 |
13 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£3360 |
12.25 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£1665 |
11.55 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
11.2 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
10.15 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
10.15 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
10.15 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
10.15 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£2495 |
10.15 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£2330 |
10 % |
Cancer Drug Discoveries: Colorectal Cancer
|
August 2005 |
£795 |
9.5 % |
Cancer Drug Discoveries: Breast Cancer
|
August 2005 |
£795 |
9.5 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2000 |
9.45 % |
Cardiovascular Drug Delivery
Technologies, Markets and Companies
|
March 2008 |
£1090 |
9.45 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£3510 |
9.1 % |
COX-2 Inhibitors
Biology, Therapeutic Agents & Markets
|
November 2004 |
£400 |
9.1 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
March 2008 |
£1390 |
8.75 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
8.5 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£2410 |
8.05 % |
Stakeholder Insight: Prostate Cancer
A Prostrate Market Waiting for Innovations
|
October 2005 |
£8695 |
8 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
7.7 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
7.7 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£4715 |
7.7 % |
Neuroprotection
Drugs, Markets and Companies
|
March 2008 |
£1740 |
7.7 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
7.5 % |
Cordis Medical Device Company Intelligence Report
|
November 2007 |
£295 |
7 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
March 2008 |
£1490 |
7 % |
Molecular Imaging Comes of Age
Applications and Impacts in Discovery, Clinical Trials, and Medical Practice
|
October 2004 |
£1950 |
6.65 % |
Takeda: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
6.65 % |
Cancer Therapeutics Markets
|
May 2008 |
£1715 |
6.65 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
6.65 % |
DePuy Medical Device Company Intelligence Report
|
December 2007 |
£295 |
6.65 % |
Cancer Therapeutics 2006
Market Dynamics and R&D Trends
|
December 2005 |
£1240 |
6 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
5.6 % |
Executive Guide to Molecular Imaging; The
|
April 2005 |
£395 |
5.6 % |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
5.6 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£3510 |
5.6 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£3510 |
5.5 % |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
5.25 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
5.25 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
4.9 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
4.9 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
4.55 % |
Gene Therapy
Technologies, Markets and Companies
|
March 2008 |
£1740 |
4.2 % |
Stakeholder Opinions
Esophageal Cancer Treatment paradigms need revolution not evolution
|
March 2007 |
£2000 |
4.2 % |
Modern Biopharmaceuticals
Design, Development and Optimization, 4 Volumes
|
September 2005 |
£440 |
3.85 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£2715 |
3.5 % |
Biomarkers
Technologies, Markets and Companies
|
March 2008 |
£1515 |
3.5 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
3.15 % |
RNAi
Technologies, Markets and Companies
|
March 2008 |
£1490 |
3.15 % |
Cell Therapy
Technologies, Markets and Companies
|
May 2008 |
£2270 |
2.8 % |
Cell Therapy Markets
|
July 2007 |
£1690 |
2.8 % |
Biological Implants
|
January 2008 |
£1885 |
2.45 % |
|
|
|
|
